-
Product Insights
Cobra Requena Solar PV Park 5
Cobra Requena Solar PV Park 5 is a solar PV project located in Valencian Community, Spain. The project is owned and being developed by Cobra Gestion De Infraestructuras SLU. The project is at the permitting stage. Empower your strategies with our Cobra Requena Solar PV Park 5 report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Product Insights
Cobra Requena Solar PV Park 1
Cobra Requena Solar PV Park 1 is a solar PV project located in Valencian Community, Spain. The project is owned and being developed by Cobra Gestion De Infraestructuras SLU. The project is at the permitting stage. Empower your strategies with our Cobra Requena Solar PV Park 1 report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-186 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-186 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: TAK-186 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-186 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-186 in Solid Tumor Drug Details: TAK-186 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-186 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-186 in Non-Small Cell Lung Cancer Drug Details: TAK-186 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-186 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-186 in Colorectal Cancer Drug Details: TAK-186 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-186 in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-186 in Pancreatic Cancer Drug Details: TAK-186 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-280 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-280 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: TAK-280 (MVC-280) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-280 in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-280 in Bladder Cancer Drug Details: TAK-280 (MVC-280) is under development for the treatment of...